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Abstract
Introduction: Heparin-induced thrombocytopenia (HIT) results from antibodies to PF4/heparin complexes and
clinical diagnosis is difficult. We evaluated the particle immunofiltration anti-platelet factor 4 (PIFA) rapid assay,
in conjunction with a clinical risk score, in the diagnosis of HIT.
Methods: We performed a prospective observational study in all patients admitted to the medical intensive care
unit (MICU) in a large academic medical center. Patients were screened daily for thrombocytopenia defined as
either a platelet count that decreased by at least 33% or an absolute platelet count less than 150,000/μL. Patients
with suspected HIT underwent PIFA and ELISA testing for anti-PF4/heparin antibodies. Available residual frozen sera
were sent to a reference laboratory for serotonin release assay (SRA) testing.
Results: During the study period, 340 patients were admitted to the MICU, of which 143 patients met criteria for
thrombocytopenia. Forty-three patients had no evidence of recent heparin exposure. PIFA and ELISA testing were
performed on 100 patients, of which 92 had samples available for SRA analysis. PIFA results were negative in 62,
positive in 28 and inconclusive in 2 patients. The 4Ts score showed low to intermediate risk in 57 of the PIFA
negative patients. The ELISA results were negative in 86 and positive in 6 patients. SRA testing identified 3 patients
with a positive SRA test and 89 patients with a negative result. All patients with a negative PIFA result also had a
negative SRA result. In the one patient deemed to have clinical HIT, the pretest probability was high (4Ts score of
6) and the anti-PF4/heparin antibody testing revealed a positive SRA, inconclusive PIFA and a negative ELISA result.
Conclusions: While thrombocytopenia in our population is common, the prevalence of HIT is low. The
combination of a low to intermediate pretest probability with a negative PIFA test can rapidly exclude the
presence of platelet activating anti-PF4/heparin antibodies and, therefore, HIT as the cause of the
thrombocytopenia. Since a positive PIFA result has a low positive predictive value, a positive PIFA is not diagnostic
of HIT and additional evaluation is warranted.
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Introduction
Heparin-induced thrombocytopenia (HIT) is a potentially
life and limb threatening, immune-mediated, pro-throm-
botic disease resulting from an interaction between plate-
lets and antibodies to platelet factor 4 (PF4)/heparin
complexes [1-3]. Thrombocytopenia is common in criti-
cally ill patients, making the diagnosis of HIT challenging
[4-6]. To assist in the diagnosis of HIT, a scoring system
called the 4Ts has been developed that incorporates a
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combination of clinical criteria associated with HIT [7].
Retrospective studies in ICU patients found that a low
probability score was unlikely to be associated with clini-
cal HIT [8,9].
Two widely used, Food and Drug Administration
(FDA)-approved solid phase ELISA assays are currently
available: Gen-Probe Lifecodes PF4 Enhanced (Gen-
Probe-Waukesha (LIFECODES) Waukesha, Wisconsin,
USA) [10] and Stago Asserachrom HPIA (Diagnostica
Stago, Inc. Parsippany, New Jersey, USA) [11]. A newer
FDA approved solid phase assay, the Particle Immunofil-
tration (PIFA) Anti-Platelet Factor 4 Rapid Assay (Akers
Biosciences, Inc. Thorofare, New Jersey, USA is run on
individual patient samples and after separation of serum
the results are available within minutes [12]. The 14C
Serotonin Release Assay (SRA) is the primary functional
assay for detection of platelet-activating anti-PF4 antibo-
dies. A positive SRA result correlates with clinically sig-
nificant anti-PF4/heparin antibodies and higher ELISA
optical density values [13-15]. A related functional test,
heparin-induced platelet aggregation, appears less sensi-
tive than the SRA assay [16]. Methods for the SRA assay
and the heparin-induced platelet aggregation test are not
standardized and are only available at specialized
laboratories.
The clinical relevance of anti-PF4/heparin antibodies
in solid phase testing is unclear, since only a subset of
the antibody response to PF4/heparin is associated with
platelet activating properties. The most commonly used
solid phase assays measure combined IgG/M/A anti-
PF4/heparin antibodies [10,11]. While IgG class antibo-
dies are most associated with platelet-activating proper-
ties, other immunoglobulin classes have also been
implicated [17]. Notably, up to half of the patients
exposed to large doses of heparin during cardiopulmon-
ary bypass procedures develop PF4/heparin antibodies,
but only approximately two percent develop platelet-
activating antibodies [18].
In critically ill patients with thrombocytopenia and
heparin exposure, the presence of anti-PF4/heparin anti-
body ranges between 10% and 30% [19,20], but the
actual incidence of HIT appears to be 1% or less [5,19].
Therefore, when a critically ill patient develops a low
platelet count, the likelihood of HIT, even with positive
antibody testing, is low. Positive SRA results have been
reported in critically ill patients without prior or current
heparin exposure, suggesting either naturally occurring
antibodies or false positive results in these patients [20].
Additionally, a relationship between bacterial sepsis and
anti-PF4/heparin antibodies has been proposed [21].
Interestingly, non-platelet-activating PF4/heparin antibo-
dies may also occur in the general population of blood
donors without heparin exposure [22] and in patients
with periodontal disease [23].
When HIT is suspected, clinicians often start non-
heparin anticoagulants prior to confirming the diagnosis.
Additionally, HIT is associated with increased cost and
financial loss to institutions [24-26]. In critically ill
patients, these alternative anticoagulants frequently
require careful dose titration, especially in patients with
organ dysfunction [27-29].
Therefore, we prospectively evaluated the Particle
Immunofiltration Anti-Platelet Factor 4 (PIFA) Rapid
Assay, in conjunction with Warkentin’s 4Ts pretest
probability in the diagnosis of HIT in the medical ICU
population.
Materials and methods
Between August 1, 2009 and April 30, 2010, patients
admitted to the MICU were screened for thrombocyto-
penia, defined as a platelet count that decreased by at
least 33% from baseline or was less than 150,000/μL.
Patients with documented heparin exposure within the
100 days prior to the development of thrombocytopenia
were classified as having been exposed to heparin.
Importantly, our medical center routinely utilizes saline
flushes for maintenance catheter patency. When heparin
flushes are used it is documented in our hospital’s com-
puterized medication administration record. Patients
with thrombocytopenia and recent heparin exposure,
without an obvious alternative cause for this thrombocy-
topenia, underwent testing for anti-PF4/heparin antibo-
dies using the Gen-Probe PF4 ELISA. Clinical HIT
required a decrease in platelet count, exposure to
heparin, laboratory confirmation of anti-PF4/heparin
antibodies and prescription of an alternative anticoagu-
lant for HIT by the primary team.
Concurrent with clinical care, and before the results of
anti-PF4 antibody tests were reported, the “4Ts score”
clinical probability score for HIT was calculated [7].
This score incorporates the degree of thrombocytopenia,
timing of platelet count decrease related to heparin
exposure, presence of thrombosis or other sequelae of
HIT and whether other causes of thrombocytopenia are
present. Patient medical and pharmacy records were
examined for prior and current use of unfractionated
heparin (UFH) and/or low-molecular-weight heparin
(LMWH) at both prophylactic and therapeutic doses.
At baseline, we collected data related to patient char-
acteristics, including length of stay in the hospital and
the MICU prior to the clinical suspicion for HIT.
Patients were followed for clinical evidence of thrombo-
tic complications and vital status until hospital discharge
or Day 60, whichever came first.
The University of Miami Institutional Review Board
determined that our study was in compliance with the
WMA Declaration of Helsinki-Ethical Principles for
Medical Research Involving Human Subjects. As this
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study compared approved platforms for testing, utilized
a limited dataset and all analysis was performed on de-
identified data, the need for informed consent was
waived. We performed our statistical analysis for the
sensitivity, specificity, positive and negative predictive
values using the statistical software JMP, (Version 9,
SAS Institute Inc., Cary, NC, USA, 1989 to 2012) and
the TI 84 calculator (Texas Instruments, Dallas, TX,
USA).
Whole blood (5 mL) was collected in non-anticoagu-
lated, plain, red-top collection tubes and sent to the
University of Miami’s Clinical Coagulation Laboratory.
In all cases, serum was separated within four hours of
blood draw as recommended by the manufacturer [12].
PIFA results were performed and recorded prior to test-
ing by the Gen-Probe PF4 ELISA method. The Gen-
Probe PF4 assay reports values in arbitrary units based
on optical density with thresholds for positive and nega-
tive results defined by the manufacturer [10]. ELISA
testing takes approximately three to four hours to per-
form with patient samples generally run in batches
[10,11]. Available residual sera were stored at -70ºC and
these specimens were sent separately in batched groups
to a reference laboratory (Quest Diagnostics Nichols
Institute, Chantilly, VA, USA) for Serotonin Release
Assay (SRA). Initially, only the Gen-Probe PF4 ELISA
results were available to the medical team for clinical
management.
The Gen-Probe PF4 ELISA platform detects serum
antibody bound to immobilized target antigen, a com-
plex between the polyanionic substrate polyvinyl sulfo-
nate (PVS) and PF4 [10]. The PVS surface serves in the
solid phase as a surrogate for heparin. Thus, patient sera
containing anti-PF4 antibody (IgG/A/M) react with PF4/
PVS in the Gen-Probe PF4 ELISA test. The threshold
for a positive result, as designated by the manufacturer,
is equal to or greater than an optical density of 0.40.
While the Gen-Probe PF4 ELISA is not approved for
use as a quantitative result, studies suggest a relation-
ship exists between optical density and risk of clinical
HIT [13].
The PIFA assay is based on the interaction of serum
anti-PF4/heparin antibody (IgG/A/M) with PF4-coated
microparticles, which are dyed blue. Patient’s serum
with anti-PF4/heparin antibodies recognize and aggre-
gate the blue-dyed microparticles, preventing their pas-
sage through a permeable membrane. This appears as
no color change/white in the TEST result window and
is considered a POSITIVE test. Patients lacking anti-PF4
antibody are not expected to cause aggregation allowing
the microparticles to traverse the permeable membrane
producing a blue color in the TEST window, which is
considered a NEGATIVE test. Each test has a control
window which appears red to indicate a satisfactory test.
After separation of serum from whole blood, PIFA
results can be available within 15 minutes.
For the SRA, the reference laboratory collects platelets
from highly reactive normal blood donors. Donor plate-
lets were loaded with 14C serotonin, washed and then
evaluated for percent release of 14C serotonin in the
presence of the patient’s sera. A threshold of greater
than 20% 14C serotonin release was the cutoff for a posi-
tive result established by the reference laboratory.
Neither Gen-Probe PF4 ELISA nor PIFA results were
made available to the reference laboratory.
Results
Of the 340 patients admitted to the MICU, 143 patients
(42%) developed thrombocytopenia. There was no evi-
dence of recent heparin exposure in 43 patients. All 100
patients with thrombocytopenia and recent heparin
exposure underwent PIFA and Gen-Probe PF4 testing.
Eight patients did not have residual sera available for
SRA analysis. Ninety-two patients underwent SRA test-
ing (Figure 1, Consort diagram) and served as the pri-
mary population for this study.
The baseline characteristics of the study population
are reported in Table 1. On average, patients were 54
years of age and were predominantly male (63%). The
average platelet count at the time of suspicion for HIT
was 96,600/μL ± 49,000/μL (mean ± SD). Prior heparin
exposure was predominantly UFH, with 75% of patients
receiving solely UFH, 5% of patients received only
Figure 1 Consort diagram.
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LMWH, and 20% of the patients receiving both UFH
and LMWH. The average Warkentin’s 4Ts score was
3.72 ± 1.12 (mean ± SD) with six patients having a high
risk 4Ts score of at least 6. The average 4Ts scores were
similar when evaluated by testing platforms and anti-
PF4 test result (Table 2).
In our study population, 62 patients had a negative
PIFA result and 28 had a positive PIFA result. In two
patients, the technologist was unable to decide whether
or not a definite color change had occurred in the test
window and these PIFA results were deemed inconclu-
sive. The Gen-Probe PF4 results were negative in 86
and positive in 6 patients (optical density greater than
0.40 units). In patients with a positive Gen-Probe PF4
the PIFA results were negative in four patients and posi-
tive in two patients (Figure 2). In general, there was
poor concordance between the PIFA and the Gen-Probe
PF4 optical density results.
SRA testing identified three patients with a positive
result and 89 patients with a negative result. One patient
was deemed to have clinical HIT with a high pretest
probability (4Ts score of 6), a clinical deep venous
thrombosis and a subsequently positive SRA (45%
release). Notably, this patient had an inconclusive PIFA
and negative Gen-Probe PF4 result. The other two
patients with a positive SRA were felt by the primary
team not to have HIT based on a low pretest probability
(4Ts scores of 2 and 3), a negative Gen-Probe PF4 result
(optical density of 0.217 and 0.083) and no clinical
thrombosis. Notably, they were not prescribed alterna-
tive anticoagulation and a SRA was not sent for clinical
purposes. In these two patients the research testing (not
available to the clinical team) revealed PIFA positive
results and weakly positive SRA results (20% and 27%
release).
To compare the PIFA to SRA results we chose to
exclude the inconclusive PIFA results. In these 90 patients,
the SRA analysis was positive in two (Table 3). Both these
patients had a positive PIFA. In the 88 patients with a
negative SRA result, the PIFA results were negative in 62
and positive in 26 patients. For the PIFA-SRA comparison,
this equates to a sensitivity of 1.0, a specificity of 0.704,
positive predictive value (PPV) of 0.071 (for a positive
PIFA test having a positive SRA result) and negative pre-
dictive value (NPV) of 1.0 (for having a negative PIFA test
also having a negative SRA result).
Table 1 Baseline characteristics of the study population.
Baseline characteristic (n = 92)
Age (years, mean ± SD) 54.4 ± 14.0
Male gender (n, percent) 58 (63%)
Platelet count units (mean ± SD) 96.6 ± 49.2
4Ts score (mean ± SD) 3.7 ± 1.1
Prior hospital days (mean ± SD) 10.2 ± 11.4
Prior ICU days (mean ± SD) 4.8 ± 5.4
Heparin exposure:
UFH (n, percent) 69 (75%)
LMWH (n, percent) 5 (5%)
Both (n, percent) 18 (20%)
LMWH, Low molecular weight heparin; SD, Standard deviation; UFH,
Unfractionated heparin
Table 2 Average Warkentin’s 4Ts score by anti-PF4 result.
PIFA (+) PIFA (-) PIFA (Inc) Gen-Probe (+) Gen-Probe (-) SRA (+) SRA (-)
(n = 28) (n = 62) (n = 2) (n = 6) (n = 86) (n = 3) (n = 89)
4Ts score
(mean ± SD)
3.76 ± 1.13 3.73 ± 1.13 3.64 ± 1.22 3.46 ± 0.91 3.72 ± 1.12 3.63 ± 1.18 3.72 ± 1.12
PIFA, Particle Immunofiltration Anti-Platelet Factor 4 Rapid Assay; SRA, Serotonin Release Assay
Figure 2 Comparison of PIFA results (positive and negative)
with the Gen-Probe PF4 optical density. An optical density of
0.40 or greater is considered a positive result. PIFA, Particle
Immunofiltration Anti-Platelet Factor 4 Rapid Assay.
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To evaluate other scenarios, we also grouped the
inconclusive PIFA findings both as positive and negative.
Grouping the two inconclusive PIFA results with the
PIFA positive cohort resulted in a sensitivity of 1.0, a
specificity of 0.6967, a PPV equal to 0.01 and a NPV of
1.00. Grouping the two inconclusive PIFA results with
the PIFA negative cohort resulted in a sensitivity in
0.667, a specificity of 0.7078, PPV equal to 0.07 and
NPV of 0.984. In our MICU population, PPV of the
PIFA, independent of how we handle the inconclusive
results, did not aid in the diagnosis of HIT.
In the six patients with a positive Gen-Probe PF4, the
average optical density was 0.761 ± 0.303 ((mean ± SD)
(range 0.501 to 1.260)). An optical density below 1.0 is
considered weakly reactive [13]. None of these patients
had a positive SRA. The Gen-Probe PF4 was negative in
86 patients. For the Gen-Probe PF4 -SRA comparison,
this equates to a sensitivity of 0.0, a specificity of 0.933,
PPV of 0.0 and NPV of 0.965. In our MICU population,
PPV of the Gen-Probe PF4 did not aid in the diagnosis
of HIT.
Discussion
Thrombocytopenia is common in the critically ill and is
associated with an increased mortality [4-6]. Due to the
numerous causes of thrombocytopenia in critically ill
patients the diagnosis of HIT is challenging. The preva-
lence of HIT in the ICU population is low, approxi-
mately one percent in both our and other studies
[5,19,20]. Because of the serious morbidity and mortality
attributable to HIT, clinicians often initiate alternative
non-heparin-based anticoagulation prior to confirming
the HIT diagnosis [24-26]. This exposes patients to the
increased risk of bleeding and higher relative costs of
alternative anticoagulants [24,26]. Inappropriately label-
ing a patient as allergic to heparin may prevent its usage
in the future, which has negative short and long-term
consequences.
The accuracy of positive results from commonly
employed laboratory diagnostic testing platforms has led
to concerns regarding the potential over-diagnosis of
HIT [14]. A rapid diagnostic test to identify patients
without anti-PF4/heparin antibodies would be of clinical
importance. Our findings suggest that, when the clinical
likelihood of HIT is low to intermediate, as measured by
a Warkentin’s 4Ts score of 1 to 5, a negative PIFA
result excluded the presence of platelet-activating anti-
PF4/heparin antibodies and, therefore, the diagnosis of
HIT. Of these 57 subjects, none had a positive SRA test
or the clinical diagnosis of HIT. The combination of a
low to intermediate clinical risk and negative PIFA test
can exclude a patient from the diagnosis of HIT prior to
the initiation of alternative anticoagulation (Figure 3).
The combined use of a pretest probability score and
laboratory testing is widely utilized in evaluating patients
with suspected venous thromboembolic (VTE) disease.
Clinicians often employ clinical predictive rules with a
negative D-dimer for exclusion of deep venous throm-
bosis (DVT) [30]. Similarly, in patients with suspected
pulmonary emboli (PE), the diagnosis can be safely
ruled out in patients with both a low pretest probability
and a negative D-dimer, reducing the need for addi-
tional costly diagnostic studies [31]. In patients with sus-
pected VTE, positive D-dimer results and/or a high pre-
test probability score direct the clinician to perform
additional diagnostic studies.
Our study highlights problems interpreting tests for
the presence of anti-PF4 antibodies. As with other anti-
PF4 antibody testing platforms, the PIFA test had an
unacceptable degree of false positive results. Of the
three patients with positive SRA results, only one was
clinically diagnosed with HIT, suggesting the other two
were falsely positive. A recent retrospective analysis
noted several patients with potentially false positive SRA
results (ELISA negative and SRA positive results) [32].
Other reports have also noted positive SRA results in
both critically ill patients without heparin exposure and
in the general population, suggesting either naturally
occurring antibodies or false positive results in these
patients [20-23].
Since no SRA reagents are FDA approved, standardi-
zation of SRA testing protocols between laboratories is
difficult and is not uniform. The percent release thresh-
old to be considered positive varies and in this study the
reference laboratory established a positive SRA as
greater than 20% release. Others have advocated a 50%
release to be considered positive [13]. Additionally, pla-
telet-activating antibodies are heterogeneous [33] and
up to 5% of samples tested will give an equivocal or
indeterminate SRA result.
Both the PIFA and Gen-Probe PF4 tests had high
negative predictive values for HIT. However, a positive
PIFA or Gen-Probe PF4 did not assist in the diagnosis
of HIT or the likelihood of having a positive SRA. The
PIFA test demonstrated a low positive predictive value
independent of how we handle the two inconclusive
tests. None of the six patients with a positive Gen-Probe
PF4 had a positive SRA. This is consistent with a
Table 3 PIFA versus SRA results*
SRA
(+) positive (-) negative
PIFA (+) positive 2 26
(-) negative 0 62
PIFA, Particle Immunofiltration Anti-Platelet Factor 4 Rapid Assay; SRA,
Serotonin Release Assay.
*Please note that for this analysis we excluded the two patients with
inconclusive PIFA results.
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previous study which found that less than 3% of patients
with a Gen-Probe PF4 optical density between 0.40 to
1.00 units demonstrated a positive SRA. Only when the
Gen-Probe PF4 optical density exceeded 1.40 units was
there an association with a strongly positive SRA [13].
All six patients from our study with a positive Gen-
Probe PF4 had an optical density less than 1.40 units.
Therefore, our data suggest that both a positive PIFA
and a weakly positive Gen-Probe PF4 result require
additional evaluation before making the diagnosis of
HIT (Figure 3).
This study has important limitations. It was conducted
in a single Medical Intensive Care Unit. While to our
knowledge this is the largest prospective trial evaluating
commonly utilized platforms to test for anti-PF4/heparin
antibodies in the critically ill population, there were still
a limited number of patients from which to draw con-
clusions. Prior studies have demonstrated a low inci-
dence of HIT in the ICU [5,19,20]. Consistent with this,
our data had relatively few patients with a high pretest
probability for HIT and we are unable to draw conclu-
sions in this patient population.
Our data cannot address the clinical significance of a
positive PIFA test. The overwhelming majority of PIFA
positive patients did not have a positive SRA result, a
high pretest probability by Warkentin’s 4Ts or a clinical
diagnosis of HIT. Therefore, our data do not support
the use of a positive PIFA in the diagnosis of HIT or to
be used as an independent criterion for administering
alternative anticoagulation. Therefore, we recommend
additional evaluation before considering the diagnosis of
HIT based on a positive PIFA.
Two of our patients had inconclusive PIFA tests and
in the latest PIFA design, the manufacturer has
employed a new color scheme in the device test window
aimed at increasing technologist performance.
Conclusions
In our critically ill medical patients with heparin expo-
sure and thrombocytopenia, a low to intermediate pret-
est probability coupled with a negative PIFA test
excluded the diagnosis of HIT. This scenario is similar
to the use of a negative D-dimer test combined with
pretest clinical probability assessment to exclude VTE
disease in the ambulatory setting. An advantage to the
PIFA testing platform is the ability to test sera from sin-
gle patients with a rapid turnaround time. Excluding a
diagnosis of HIT on a near real-time basis can prevent
Figure 3 Proposed clinical suspicion of HIT in the ICU population diagnostic flow diagram. HIT, Heparin-induced thrombocytopenia; ICU,
Intensive care unit.
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use of costly and potentially dangerous alternative
anticoagulants.
Key messages
• Both a negative PIFA test and Gen-Probe PF4 have
a high negative predictive value for the presence of
platelet activating anti-PF4/heparin antibodies.
• The PIFA test is performed on individual patient
samples and results are rapidly available.
• The clinical significance of a positive PIFA result is
unknown and warrants further evaluation.
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